
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Canada's total of approximately 619 full-time dermatologists averages out to one per 55,000 residents (the American Academy of Dermatology recommends one per 40,000).